In silico identification and biological evaluation of a selective MAP4K4 inhibitor against pancreatic cancer

References

• Rawla P, Sunkara T, Gaduputi V. Epidemiology of pancreatic cancer: global trends, etiology and risk factors. World J Oncol. 2019;10(1):10–27.
   PubMedGoogle Scholar
• Klein AP, Brune KA, Petersen GM, Goggins M, Tersmette AC, Offerhaus GJ, Griffin C, Cameron JL, Yeo CJ, Kern S, et al. Prospective risk of pancreatic cancer in familial pancreatic cancer kindreds. Cancer Res. 2004;64(7):2634–2638.
   Google Scholar
• Robatel S, Schenk M. Current limitations and novel perspectives in pancreatic cancer treatment. Cancers. 2022;14(4):985.
   PubMed Web of Science ®Google Scholar
• Wong A, Soo RA, Yong WP, Innocenti F. Clinical pharmacology and pharmacogenetics of gemcitabine. Drug Metab Rev. 2009;41(2):77–88.
   PubMed Web of Science ®Google Scholar
• Oberstein PE, Olive KP. Pancreatic cancer: why is it so hard to treat? Therap Adv Gastroenterol. 2013;6(4):321–337.
   PubMed Web of Science ®Google Scholar
• Jiang B, Zhou L, Lu J, Wang Y, Liu C, You L, Guo J. Stroma-targeting therapy in pancreatic cancer: one coin with two sides? Front Oncol. 2020; 10(10):576399.
   PubMedGoogle Scholar
• Delpire E. The mammalian family of sterile 20p-like protein kinases. Pflugers Arch. 2009;458(5):953–967.
   PubMed Web of Science ®Google Scholar
• Vitorino P, Yeung S, Crow A, Bakke J, Smyczek T, West K, McNamara E, Eastham-Anderson J, Gould S, Harris SF, et al. MAP4K4 regulates integrin-FERM binding to control endothelial cell motility. Nature. 2015;519(7544):425–430.
   PubMed Web of Science ®Google Scholar
• Tang X, Guilherme A, Chakladar A, Powelka AM, Konda S, Virbasius JV, Nicoloro SM, Straubhaar J, Czech MP. An RNA interference-based screen identifies MAP4K4/NIK as a negative regulator of PPARgamma, adipogenesis, and insulin-responsive hexose transport. Proc Natl Acad Sci U S A. 2006;103(7):2087–2092.
   PubMed Web of Science ®Google Scholar
• Gao X, Gao C, Liu G, Hu J. MAP4K4: An emerging therapeutic target in cancer. Cell Biosci. 2016;6:56.
   PubMed Web of Science ®Google Scholar
• Collins CS, Hong J, Sapinoso L, Zhou Y, Liu Z, Micklash K, Schultz PG, Hampton GM. A small interfering RNA screen for modulators of tumor cell motility identifies MAP4K4 as a promigratory kinase. Proc Natl Acad Sci U S A. 2006;103(10):3775–3780.
   PubMed Web of Science ®Google Scholar
• Gao X, Chen G, Gao C, Zhang DH, Kuan SF, Stabile LP, Liu G, Hu J. MAP4K4 is a novel MAPK/ERK pathway regulator required for lung adenocarcinoma maintenance. Mol Oncol. 2017;11(6):628–639.
   PubMed Web of Science ®Google Scholar
• Prolo LM, Li A, Owen SF, Parker JJ, Foshay K, Nitta RT, Morgens DW, Bolin S, Wilson CM, Vega LJ, et al. Targeted genomic CRISPR-Cas9 screen identifies MAP4K4 as essential for glioblastoma invasion. Sci Rep. 2019;9(1):14020.
   PubMedGoogle Scholar
• Singh SK, Kumar S, Viswakarma N, Principe DR, Das S, Sondarva G, Nair RS, Srivastava P, Sinha SC, Grippo PJ, et al. MAP4K4 promotes pancreatic tumorigenesis via phosphorylation and activation of mixed lineage kinase 3. Oncogene. 2021;40(43):6153–6165.
   PubMed Web of Science ®Google Scholar
• Liang JJ, Wang H, Rashid A, Tan T-H, Hwang RF, Hamilton SR, Abbruzzese JL, Evans DB, Wang H. Expression of MAP4K4 is associated with worse prognosis in patients with stage II pancreatic ductal adenocarcinoma. Clin Cancer Res. 2008;14(21):7043–7049.
   PubMed Web of Science ®Google Scholar
• Liu YF, Qu GQ, Lu YM, Kong WM, Liu Y, Chen WX, Liao XH. Silencing of MAP4K4 by short hairpin RNA suppresses proliferation, induces G1 cell cycle arrest and induces apoptosis in gastric cancer cells. Mol Med Rep. 2016;13(1):41–48.
   PubMed Web of Science ®Google Scholar
• Liu H, Su YC, Becker E, Treisman J, Skolnik EY. A Drosophila TNF-receptor-associated factor (TRAF) binds the ste20 kinase Misshapen and activates Jun kinase. Curr Biol. 1999;9(2):101–104.
   PubMed Web of Science ®Google Scholar
• Xin W, Yun KJ, Ricci F, Zahurak M, Qiu W, Su GH, Yeo CJ, Hruban RH, Kern SE, Iacobuzio-Donahue CA. Map2k4/mkk4 expression in pancreatic cancer: Genetic validation of immunohistochemistry and relationship to disease course. Clin Cancer Res. 2004;10(24):8516–8520.
   PubMed Web of Science ®Google Scholar
• Yao Z, Zhou G, Wang XS, Brown A, Diener K, Gan H, Tan TH. A novel human STE20-related protein kinase, HGK, that specifically activates the c-Jun N-terminal kinase signaling pathway. J Biol Chem. 1999;274(4):2118–2125.
   PubMed Web of Science ®Google Scholar
• Hickson JA, Huo D, Vander Griend DJ, Lin A, Rinker-Schaeffer CW, Yamada SD. The p38 kinases MKK4 and MKK6 suppress metastatic colonization in human ovarian carcinoma. Cancer Res. 2006;66(4):2264–2270.
   PubMed Web of Science ®Google Scholar
• Davis RJ. Signal transduction by the JNK group of MAP kinases. Cell. 2000;103(2):239–252.
   PubMed Web of Science ®Google Scholar
• Dou Y, Jiang X, Xie H, He J, Xiao S. The Jun N-terminal kinases signaling pathway plays a "seesaw" role in ovarian carcinoma: a molecular aspect. J Ovarian Res. 2019;12(1):99.
   PubMed Web of Science ®Google Scholar
• Seki E, Brenner DA, Karin M. A liver full of JNK: signaling in regulation of cell function and disease pathogenesis, and clinical approaches. Gastroenterology. 2012;143(2):307–320.
   PubMed Web of Science ®Google Scholar
• Bogoyevitch MA, Kobe B. Uses for JNK: The many and varied substrates of the c-Jun N-terminal kinases. Microbiol Mol Biol Rev. 2006;70(4):1061–1095.
   PubMed Web of Science ®Google Scholar
• Tournier C. The 2 faces of JNK signaling in cancer. Genes Cancer. 2013;4(9-10):397–400.
   PubMedGoogle Scholar
• Morrison DK. Map kinase pathways. Cold Spring Harb Perspect Biol. 2012;4(11):a011254–a011254.
   PubMed Web of Science ®Google Scholar
• Tam SY, Law HK. JNK in tumor microenvironment: present findings and challenges in clinical translation. Cancers. 2021;13(9):2196.
   PubMed Web of Science ®Google Scholar
• Ammirati M, Bagley SW, Bhattacharya SK, Buckbinder L, Carlo AA, Conrad R, Cortes C, Dow RL, Dowling MS, El-Kattan A, et al. Discovery of an in vivo tool to establish proof-of-concept for map4k4-based antidiabetic treatment. ACS Med Chem Lett. 2015;6(11):1128–1133.
   PubMed Web of Science ®Google Scholar
• Ndubaku CO, Crawford TD, Chen H, Boggs JW, Drobnick J, Harris SF, Jesudason R, McNamara E, Nonomiya J, Sambrone A, et al. Structure-based design of GNE-495, a potent and selective MAP4K4 inhibitor with efficacy in retinal angiogenesis. ACS Med Chem Lett. 2015;6(8):913–918.
   PubMed Web of Science ®Google Scholar
• Bickerton GR, Paolini GV, Besnard J, Muresan S, Hopkins AL. Quantifying the chemical beauty of drugs. Nat Chem. 2012;4(2):90–98.
   PubMed Web of Science ®Google Scholar
• Lipinski CA, Lombardo F, Dominy BW, Feeney PJ. Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings. Adv Drug Deliv Rev. 2001;46(1–3):3–26.
   PubMed Web of Science ®Google Scholar
• Lipinski CA. Lead- and drug-like compounds: the rule-of-five revolution. Drug Discov Today Technol. 2004;1(4):337–341.
   PubMedGoogle Scholar
• Veber DF, Johnson SR, Cheng HY, Smith BR, Ward KW, Kopple KD. Molecular properties that influence the oral bioavailability of drug candidates. J Med Chem. 2002;45(12):2615–2623.
   PubMed Web of Science ®Google Scholar
• Baell J, Walters MA. Chemistry: chemical con artists foil drug discovery. Nature. 2014;513(7519):481–483.
   PubMed Web of Science ®Google Scholar
• Schneider N, Lange G, Hindle S, Klein R, Rarey M. A consistent description of hydrogen bond and dehydration energies in protein-ligand complexes: Methods behind the hyde scoring function. J Comput Aided Mol Des. 2013;27(1):15–29.
   Google Scholar
• Böhm H-J. On the use of LUDI to search the Fine Chemicals Directory for ligands of proteins of known three-dimensional structure. J Comput Aided Mol Des. 1994;8(5):623–632.
   PubMed Web of Science ®Google Scholar
• Berman HM, Westbrook J, Feng Z, Gilliland G, Bhat TN, Weissig H, Shindyalov IN, Bourne PE. The protein data bank. Nucleic Acids Res. 2000;28(1):235–242.
   PubMed Web of Science ®Google Scholar
• Cresset. Forge. 10.4.2. Litlington, Cambridgeshire: Cresset; 2015.
   Google Scholar
• Chao MW, Lin TE, HuangFu WC, Chang CD, Tu HJ, Chen LC, Yen SC, Sung TY, Huang WJ, Yang CR, et al. Identification of a dual taok1 and map4k5 inhibitor using a structure-based virtual screening approach. J Enzyme Inhib Med Chem. 2021;36(1):98–108.
   PubMed Web of Science ®Google Scholar
• Yen SC, Chen LC, Huang HL, HuangFu WC, Chen YY, Eight Lin T, Lien ST, Tseng HJ, Sung TY, Hsieh JH, et al. Identification of a dual FLT3 and MNK2 inhibitor for acute myeloid leukemia treatment using a structure-based virtual screening approach. Bioorg Chem. 2022;121:105675.
   PubMed Web of Science ®Google Scholar
• Yen SC, Chen LC, Huang HL, Ngo ST, Wu YW, Lin TE, Sung TY, Lien ST, Tseng HJ, Pan SL, et al. Investigation of selected flavonoid derivatives as potent FLT3 inhibitors for the potential treatment of acute myeloid leukemia. J Nat Prod. 2021;84(1):1–10.
   PubMed Web of Science ®Google Scholar
• Goldman MJ, Craft B, Hastie M, Repecka K, McDade F, Kamath A, Banerjee A, Luo Y, Rogers D, Brooks AN, et al. Visualizing and interpreting cancer genomics data via the Xena platform. Nat Biotechnol. 2020;38(6):675–678.
   PubMed Web of Science ®Google Scholar
• Ritchie ME, Phipson B, Wu D, Hu Y, Law CW, Shi W, Smyth GK. Limma powers differential expression analyses for RNA-sequencing and microarray studies. Nucleic Acids Res. 2015;43(7):e47.
   PubMed Web of Science ®Google Scholar
• Weinstein JN, Collisson EA, Mills GB, Shaw KR, Ozenberger BA, Ellrott K, Shmulevich I, Sander C, Stuart JM. The cancer genome atlas pan-cancer analysis project. Nat Genet. 2013;45(10):1113–1120.
   PubMed Web of Science ®Google Scholar
• Colaprico A, Silva TC, Olsen C, Garofano L, Cava C, Garolini D, Sabedot TS, Malta TM, Pagnotta SM, Castiglioni I, et al. TCGAbiolinks: an R/Bioconductor package for integrative analysis of TCGA data. Nucleic Acids Res. 2016;44(8):e71–e71.
   PubMed Web of Science ®Google Scholar
• Plouffe SW, Meng Z, Lin KC, Lin B, Hong AW, Chun JV, Guan KL. Characterization of hippo pathway components by gene inactivation. Mol Cell. 2016;64(5):993–1008.
   PubMed Web of Science ®Google Scholar
• Meng Z, Moroishi T, Mottier-Pavie V, Plouffe SW, Hansen CG, Hong AW, Park HW, Mo JS, Lu W, Lu S, et al. MAP4K family kinases act in parallel to MST1/2 to activate LATS1/2 in the Hippo pathway. Nat Commun. 2015; 6(6):8357.
   PubMedGoogle Scholar
• Chen R, Xie R, Meng Z, Ma S, Guan KL. STRIPAK integrates upstream signals to initiate the Hippo kinase cascade. Nat Cell Biol. 2019;21(12):1565–1577.
   PubMed Web of Science ®Google Scholar
• Bae SJ, Luo X. Activation mechanisms of the Hippo kinase signaling cascade. Biosci Rep. 2018;38(4):BSR20171469.
   PubMedGoogle Scholar
• Ling Q, Li F, Zhang X, Mao S, Lin X, Pan J, Ye W, Wei W, Qian Y, Hu C, et al. MAP4K1 functions as a tumor promotor and drug mediator for AML via modulation of DNA damage/repair system and MAPK pathway. EBioMedicine. 2021;69:103441.
   PubMed Web of Science ®Google Scholar
• Chuang HC, Tan TH. Map4k3/glk in autoimmune disease, cancer and aging. J Biomed Sci. 2019;26(1):82.
   PubMed Web of Science ®Google Scholar
• Wang OH, Azizian N, Guo M, Capello M, Deng D, Zang F, Fry J, Katz MH, Fleming JB, Lee JE, et al. Prognostic and functional significance of map4k5 in pancreatic cancer. PLoS One. 2016;11(3):e0152300.
   PubMed Web of Science ®Google Scholar
• Torres-Ayuso P, An E, Nyswaner KM, Bensen RC, Ritt DA, Specht SI, Das S, Andresson T, Cachau RE, Liang RJ, et al. TNIK is a therapeutic target in lung squamous cell carcinoma and regulates FAK activation through merlin. Cancer Discov. 2021;11(6):1411–1423.
   PubMed Web of Science ®Google Scholar
• Harvey KF, Zhang X, Thomas DM. The Hippo pathway and human cancer. Nat Rev Cancer. 2013;13(4):246–257.
   PubMed Web of Science ®Google Scholar
• Johnson R, Halder G. The two faces of Hippo: targeting the Hippo pathway for regenerative medicine and cancer treatment. Nat Rev Drug Discov. 2014;13(1):63–79.
   PubMed Web of Science ®Google Scholar
• Chuang HC, Tan TH. MAP4K family kinases and DUSP family phosphatases in t-cell signaling and systemic lupus erythematosus. Cells. 2019;8(11):1433.
   PubMed Web of Science ®Google Scholar
• Dow RL, Ammirati M, Bagley SW, Bhattacharya SK, Buckbinder L, Cortes C, El-Kattan AF, Ford K, Freeman GB, Guimaraes CRW, et al. 2-Aminopyridine-based mitogen-activated protein kinase kinase kinase kinase 4 (MAP4K4) inhibitors: assessment of mechanism-based safety. J Med Chem. 2018;61(7):3114–3125.
   PubMed Web of Science ®Google Scholar
• Fu Y, Liu X, Chen Q, Liu T, Lu C, Yu J, Miao Y, Wei J. Downregulated mir-98-5p promotes PDAC proliferation and metastasis by reversely regulating MAP4K4. J Exp Clin Cancer Res. 2018;37(1):130.
   PubMedGoogle Scholar
• Rayter S, Elliott R, Travers J, Rowlands MG, Richardson TB, Boxall K, Jones K, Linardopoulos S, Workman P, Aherne W, et al. A chemical inhibitor of PPM1D that selectively kills cells overexpressing PPM1D. Oncoge1qne. 2008;27(8):1036–1044.
   PubMed Web of Science ®Google Scholar
• Yenugonda V, Nomura N, Kouznetsova V, Tsigelny I, Fogal V, Nurmemmedov E, Kesari S, Babic I. A novel small molecule inhibitor of p32 mitochondrial protein overexpressed in glioma. J Transl Med. 2017;15(1):210.
   PubMedGoogle Scholar
• Badea L, Herlea V, Dima SO, Dumitrascu T, Popescu I. Combined gene expression analysis of whole-tissue and microdissected pancreatic ductal adenocarcinoma identifies genes specifically overexpressed in tumor epithelia. Hepatogastroenterology. 2008;55(88):2016–2027.
   PubMedGoogle Scholar
• Tripolitsioti D, Grotzer M, Baumgartner M. The Ser/Thr kinase MAP4K4 controls pro-metastatic cell functions. J Carcinog Mutagen. 2017;08(01):2157–2518.
   Google Scholar
• Abrahams G, Newman J. Data- and diversity-driven development of a shotgun crystallization screen using the protein data bank. Acta Crystallogr D Struct Biol. 2021;77(Pt 11):1437–1450.
   PubMedGoogle Scholar
• Adams PD, Afonine PV, Baskaran K, Berman HM, Berrisford J, Bricogne G, Brown DG, Burley SK, Chen M, Feng Z, et al. Announcing mandatory submission of PDBx/mmCIF format files for crystallographic depositions to the protein data bank (PDB). Acta Crystallogr D Struct Biol. 2019;75(4):451–454.
   PubMedGoogle Scholar
• Li Z, Xuan Z, Chen J, Song W, Zhang S, Jin C, Zhou M, Zheng S, Song P. Inhibiting the NF-κb pathway enhances the antitumor effect of cabazitaxel by downregulating Bcl-2 in pancreatic cancer. Int J Oncol. 2020;57(1):161–170.
   PubMed Web of Science ®Google Scholar
• Gao J, Long B, Wang Z. Role of notch signaling pathway in pancreatic cancer. Am J Cancer Res. 2017;7(2):173–186.
   PubMed Web of Science ®Google Scholar
• Cuenda A, Dorow DS. Differential activation of stress-activated protein kinase kinases SKK4/MKK7 and SKK1/MKK4 by the mixed-lineage kinase-2 and mitogen-activated protein kinase kinase (MKK) kinase-1. Biochem J. 1998;333(1):11–15.
   PubMedGoogle Scholar